Satyam’s recovered a lot and I’m moving it out of the Short Only Strategy – one contract, about 10 bucks as a loss, which is around 6,000 Rupees. Not too bad, and the stop loss was the entry price, which was crossed today.
We are still at 11.87% on the SoS, for about four months. The next year should be good for shorts. Am eagerly awaiting results season.
Happy New Year everyone. Shall make a fresh post tomorrow. Meanwhile, stay safe.
Natco Pharma, a leader in APIs and niche generics, faces growth challenges post-Revlimid exclusivity in FY26, with semaglutide offering long-term ...
TARIL is one of the leading transformer manufacturers in India, and with the country’s growing power demand, the company is well-positioned to play a crucial ...
Jubilant Pharmova is a multifaceted pharma player, standing amidst a blend of growth and transformation. While some its segments are showing robust growth ...